Search results for "biomarqueur"

showing 10 items of 16 documents

Low level activity thresholds for changes in NMR biomarkers and genes in high risk subjects for type 2 diabetes

2017

AbstractOur objectives were to determine if there are quantitative associations between amounts and intensities of physical activities (PA) on NMR biomarkers and changes in skeletal muscle gene expressions in subjects with high risk for type 2 diabetes (T2D) performing a 3-month PA intervention. We found that PA was associated with beneficial biomarker changes in a factor containing several VLDL and HDL subclasses and lipids in principal component analysis (P = <0.01). Division of PA into quartiles demonstrated significant changes in NMR biomarkers in the 2nd - 4th quartiles compared to the 1st quartile representing PA of less than 2850 daily steps (P = 0.0036). Mediation analysis of PA-…

0301 basic medicineBlood GlucoseMaleVery low-density lipoprotein[SDV]Life Sciences [q-bio]prévention des maladieslcsh:MedicineAdipose tissueMuscle ProteinsType 2 diabetes030204 cardiovascular system & hematologyOverweight0302 clinical medicinemaladie cardiovasculairelcsh:ScienceComputingMilieux_MISCELLANEOUSBODY-WEIGHT CHANGEMultidisciplinaryMiddle AgedMagnetic Resonance Imaging[SDV] Life Sciences [q-bio]ADIPOSE-TISSUEBiomarker (medicine)SKELETAL-MUSCLEFemalemedicine.symptombiomarqueurINSULIN-RESISTANCE ATHEROSCLEROSISAutre (Sciences du Vivant)Adultmedicine.medical_specialtydiabète de type 2expression géniqueCarbohydrate metabolismALL-CAUSEArticle03 medical and health sciencesMedical researchLIPID-METABOLISMInternal medicineDiabetes mellitusmedicineAPOLIPOPROTEIN-D POLYMORPHISMHumansObesityNUCLEAR-MAGNETIC-RESONANCEMuscle SkeletalExercisebusiness.industryMORTALITYlcsh:RLipid metabolismsurpoidsLIPOPROTEIN PARTICLE-SIZEmedicine.disease030104 developmental biologyEndocrinologyPHYSICAL-ACTIVITYDiabetes Mellitus Type 2Gene Expression Regulationlcsh:QbusinessBiomarkers
researchProduct

Intérêt du growth differentiation factor 15 (GDF15) comme biomarqueur pronostique après la survenue d'un Accident Vasculaire Cérébral ischémique (AVC)

2018

Introduction Le GDF15 est un biomarqueur de mauvais pronostic dans certaines pathologies cardiovasculaires comme le syndrome coronarien aigu. Son interet dans le domaine de AVC n’a ete que peu etudie a ce jour. Objectifs Notre travail consistait a l’evaluation des taux de GDF15 chez des patients hospitalises a la phase aigue d’un AVC ischemique traites par fibrinolyse et/ou thrombectomie. L’objectif principal etait d’evaluer l’association entre les taux de GDF15 et la recuperation fonctionnelle a 3 mois. Methodes Au total, 174 patients ont ete inclus entre le 16/01 et le 30/09/2017. Le consentement etait recueilli oralement. Des prelevements biologiques ont ete realises a l’admission du pat…

AVC03 medical and health sciencesRevascularisation0302 clinical medicineBiomarqueurNeurology[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]030212 general & internal medicineNeurology (clinical)ischémique[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology030217 neurology & neurosurgery
researchProduct

Nouvelles stratégies innovantes en immunothérapie

2018

Resume Les progres recents de l’immunotherapie en oncologie avec le developpement des anticorps anti-PD1/PD-L1 revolutionnent la prise en charge oncologique. L’immuno-oncologie se developpe ainsi dans la plupart des types histologiques de cancer. Malgre tout, l’utilisation des anticorps anti-PD1/PD-L1 en monotherapie est limitee par une reponse restreinte a une sous-population de malades representant environ 25-30 % des patients dans la plupart des indications. Le developpement de nouvelles strategies se base sur cette observation. Ainsi on note le developpement de differentes strategies ayant pour objectifs de mieux selectionner les malades ou de combiner les checkpoints inhibiteurs avec d…

BiomarqueursGynecology0303 health sciencesCancer Researchmedicine.medical_specialtybusiness.industryImmunothérapieImmune checkpoint inhibitorsChimio-immunothérapie[SDV.CAN]Life Sciences [q-bio]/CancerHematologyGeneral Medicine3. Good health03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesisMedicineRadiology Nuclear Medicine and imagingImmunotherapybusinessBiomarkersCheckpoint inhibitors030304 developmental biologyBulletin du Cancer
researchProduct

Evaluation of proton MR spectroscopy at 3 Tesla without endorectal coil in patients with a localized prostate cancer treated with exclusive radiother…

2011

Prostate cancer is the most frequent tumour affecting the male population. When the prostate is not removed and is treated with radiation therapy, PSA slowly decreases over time to reach its nadir, even sometimes 18 to 24 months after the completion of radiation therapy without combined androgen suppression therapy. When combined with hormones, PSA falls abruptely with no possibility to perceive the impact of either hormones or radiation effects on PSA.The optimal value of PSA that should be reached after radiation therapy (nadir) and time to this nadir are still unclear.Even when a satisfactory value of the PSA nadir is reached, on-going variations of the PSA and its “bounce” effects, whic…

BiomarqueursRéponse thérapeutique[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyProstate cancerTherapeutic responseRadiotherapySpectroscopieCancer de la prostateIRM fonctionnelle[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyBiomarkersSpectroscopy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFunctional MRIRadiothérapie
researchProduct

Involvment of docosanoïc acid (C22=0), and of very long chain fatty acids (tetracosanoïc acid (C24=0), hexacosanoïc acid (C26=0) in Alzheimer's disea…

2013

In the brain and in the plasma of patients with Alzheimer’s disease (AD), marked accumulation of C22:0 and of very long chain fatty acids (C24:0 ; C26:0) have been reported. Important decreases of docosahexaenoic acid (DHA; C22:6 n-3) have also been described as well as quantitative and qualitative modifications of plasmalogens. Altogether, these lipid modifications suggest an implication of peroxisomal metabolism disorders in the physiopathology of AD. Therefore, the biological activities of C22:0, C24:0 and C26:0 have been studied on human neuronal cells SK-N-BE. On these cells, the lipotoxicity of fatty acids (C22:0, C24:0 and C26:0) leads to various cellular modifications: topographical…

Biomarqueurs[SDV.SA] Life Sciences [q-bio]/Agricultural sciences[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyHexacosanoic acid (C26:0)Acide hexacosanoique (C26:0)Souris transgénique APP PS1 ΔE9Transgenic mouse APP PS1 ΔE9PeroxisomeMaladie d’AlzheimerAcides gras à très longue chaîneVery long chain fatty acidsLipotoxicitéTetracosanoic acid (C24:0)Docosanoic acid (C22:0)DemenciaDémencesAcide tétracosanoique (C24:0)PeroxysomeAcide docosanoIque (C22:0)Alzheimer’s diseaseBiomarkersLipotoxicity
researchProduct

Chirurgie cardiaque sous circulation extra-corporelle et ses biomarqueurs : rôle du Growth / Différentiation Factor 15 (GDF 15) : études cliniques

2016

Ischemic cardiac diseases are the most frequent and deleterious pathologies leading to important cardiovascular-related mortality worldwide. One of the alternative therapies consists to treat these patients using cardiac surgery. Cardiopulmonary bypass was developed to greatly improve this surgical procedure. However, some adverse effects can occur during cardiac surgery associated with cardiopulmonary bypass due to the inflammatory response. This phenomenon is the result of various mechanisms including oxidative stress and inflammatory cytokines which lead to multi-organ failure and then to myocardial and renal injuries occurring during the peri- and post-operative periods.The first part o…

Inflammation[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyChirurgie cardiaqueInsuffisance rénale aigue[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesCirculation extracorporelleStratification du risqueAcute kidney injuryGDF-15[SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciencesThoracic surgery[ SDV.SP ] Life Sciences [q-bio]/Pharmaceutical sciencesBiomarqueurGrowth differentiation factor 15[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathologyExtracorporeal circulation[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBiomarkersRisk assessment
researchProduct

Identification of predictive biomarkers for the efficacy of nivolumab in patients with advanced non-small cell cancer.

2019

The recent introduction of immunotherapy has disrupted the management of non-small cell lung cancer (NSCLC). Nivolumab, an antibody targeting the immune checkpoint inhibitor PD-1, has shown remarkable results in seconde-line setting after failure of standard first-line chemotherapy. However, only a quarter of patients benefits from this therapy. To date, no predictive biomarker of the therapeutic efficacy of nivolumab has been identified in a clear and consensual manner. The research for predictive biomarkers of efficacy or resistance to this treatment is, therefore, a major challenge.The emergence of high-throughput sequencing over the past decade has had a significant impact on clinical a…

Predictive modelsBiomarqueursModèles prédictifs[SDV.MHEP] Life Sciences [q-bio]/Human health and pathologyLung cancersCancers bronchiquesImmunothérapieNext-Generation sequencingImmunotherapy[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyBiomarkersSéquençage nouvelle génération
researchProduct

Dépistage du cancer du sein : en route vers le futur

2016

Breast cancer remains a potentially lethal disease, which requires aggressive treatments and is associated with long-term consequences. Its prognosis is linked to both tumor biology and burden at diagnosis. Although treatments have allowed important improvements in prognosis over the past 20 years, breast cancer screening remains necessary. Mammographic screening allows earlier stage diagnoses and a decrease of breast cancer specific mortality. However, breast cancer screening modalities should be revised with the objective to address demonstrated limitations of mammographic screening (limited benefit, imperfect sensitivity and specificity, overdiagnoses, radiation-induced morbidity). Furth…

RiskCancer Researchmedicine.medical_specialtyPersonalized[SDV.CAN]Life Sciences [q-bio]/CancerDiseaseRisque03 medical and health sciencesBreast cancer screening0302 clinical medicineBreast cancerBreast cancer[SDV.CAN] Life Sciences [q-bio]/CancerPersonnalisémedicineMammographyRadiology Nuclear Medicine and imaging030212 general & internal medicineIntensive care medicineScreening proceduresCancer du seinBiomarqueursCancer preventionmedicine.diagnostic_testbusiness.industryHematologyGeneral Medicinemedicine.disease3. Good healthClinical trialOncologyDépistage030220 oncology & carcinogenesisScreeningBiomarker (medicine)businessBiomarkers
researchProduct

Projet SALAMANDER : Biomarqueurs salivaires du régime méditerranéen associés à une protection au long terme contre le diabète de type 2

2017

[SDV.AEN] Life Sciences [q-bio]/Food and NutritionUKBiobank[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieépidémiologie[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiediète méditerranéennebiomarqueurs[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionsalive
researchProduct

Identification of a circulating biomarker highly associated to retinal omega-3 polyunsaturated fatty acid content: the BLISAR project

2019

International audience

[SDV.AEN] Life Sciences [q-bio]/Food and Nutrition[SDV.MHEP.OS] Life Sciences [q-bio]/Human health and pathology/Sensory Organsrétinelipides[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory Organshumainbiomarqueur[SDV.AEN]Life Sciences [q-bio]/Food and NutritionComputingMilieux_MISCELLANEOUS
researchProduct